The Nordic life sciences scene is getting an injection of cash. Led by centers such as the Karolinska Institutet and Copenhagen University, the region leads the way in research in the EU by many…
Totus Medicines is making a play for the PI3Kα inhibitor market. Exiting stealth with a $40 million series A round, the Massachusetts-based biotech plans to advance a molecule designed to improve on…
K36 Therapeutics launched with $30 million to bankroll the clinical entry of a multiple myeloma small-molecule in-licensed from Novartis. The oral drug targets a subset of the plasma cell cancer that…
Chan Zuckerberg Initiative to pour $3.4B over 10 years into AI, imaging and other tech to unravel biomedical challenges
apark
Thu, 12/09/2021 – 11:28
Lynn Carroll and John Schwartz Lynn Carroll is the chief operations officer and John Schwartz, the chief revenue officer of HSBlox, which assists healthcare stakeholders at the intersection of value-based care and precision health with a secure, information-rich approach to event-based, patient-centric digital healthcare processes – empowering whole health in traditional care settings, the home …
Lynn Carroll and John Schwartz, Author at MedCity News Read More »
FDA authorization of AstraZeneca drug Evusheld makes it the first antibody therapy for preventing infection before exposure to Covid-19, providing an option for immunocompromised patients who won’t…
The company is working on a voice assistant to lighten clinicians’ documentation burdens by automating some of that work. It faces competition from large companies like Nuance, which was acquired by…
Existing claims and clinical workflow-based legacy technology investments, both on the payer and provider sides, simply are not equipped to efficiently administer value-based arrangements at scale.
At its first investor day since the start of the pandemic, CVS Health detailed plans to open primary care centers and integrate them with its other health services. At the same time, CVS plans to…
Vaccine makers’ indemnification requirements are preventing doses from reaching the world’s 170 million refugees and other displaced people.
